A champion of exploring new frontiers as a scientific leader and company builder, with deep expertise in applying machine learning and computational technologies to drug discovery and development. Rosana co-founded ROME Therapeutics — the leading company illuminating the role of the dark genome in human health and disease — as the first-ever entrepreneur-in-residence at GV (formerly Google Ventures), where she is currently a Life Sciences Fellow. Prior to launching ROME, Rosana was the founding Chief Scientific Officer of Nimbus Therapeutics, where she led the company’s application of advanced computational technologies to the design and development of novel therapeutics. Most notably, Rosana led Nimbus’ discovery efforts for programs targeting acetyl-CoA carboxylase (ACC) and tyrosine kinase 2 (TYK2), which were acquired in blockbuster deals by Gilead and Takeda respectively.
Across her entire career, Rosana has raised more than $250 million in venture capital funding and mentored many of today’s industry leaders. She has consulted for Third Rock Ventures and Atlas Venture, is a member of the board of directors of Schrödinger and sits on the key advisory board for the Blavatnik Fellowship in Life Science Entrepreneurship at Harvard Business School.
Recognitions Rosana has received include selection for the Forbes 50 Over 50 Entrepreneurs list (2022), the Endpoints Women in Biopharma list (2019) and Fierce Pharma Fiercest Women in Life Sciences (2019). Rosana earned her MD from Universidade do Estado do Rio de Janeiro in Brazil and her PhD in Molecular and Cellular Biology from Tufts University.
CEO, ROME Therapeutics
Join our email list to receive exclusive offers